AJOVY Drug Profile
✉ Email this page to a colleague
Summary for Tradename: AJOVY
| High Confidence Patents: | 3 |
| Applicants: | 1 |
| BLAs: | 1 |
| Drug Prices: | Drug price information for AJOVY |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for AJOVY |
Recent Litigation for AJOVY
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Teva Pharmaceuticals International GmbH v. Eli Lilly and Company | 2018-09-27 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Eli Lilly and Company | 2018-09-28 |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for AJOVY Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for AJOVY Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Teva Branded Pharmaceutical Products R&d, Inc. | AJOVY | fremanezumab-vfrm | Injection | 761089 | ⤷ Try a Trial | 2025-11-14 | Company disclosures |
| Teva Branded Pharmaceutical Products R&d, Inc. | AJOVY | fremanezumab-vfrm | Injection | 761089 | ⤷ Try a Trial | 2025-11-14 | Company disclosures |
| Teva Branded Pharmaceutical Products R&d, Inc. | AJOVY | fremanezumab-vfrm | Injection | 761089 | ⤷ Try a Trial | 2034-03-21 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for AJOVY Derived from Patent Text Search
No patents found based on company disclosures
International Patents for AJOVY
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Ukraine | 94244 | ⤷ Try a Trial |
| Hungary | E036940 | ⤷ Try a Trial |
| Spain | 2433251 | ⤷ Try a Trial |
| Cyprus | 1120249 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for AJOVY
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 30/2019 | Austria | ⤷ Try a Trial | PRODUCT NAME: GALCANEZUMAB; REGISTRATION NO/DATE: EU/1/18/1330 (MITTEILUNG) 20181116 |
| 132019000000067 | Italy | ⤷ Try a Trial | PRODUCT NAME: GALCANEZUMAB(EMGALITY ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1330, 20181116 |
| 2019C/524 | Belgium | ⤷ Try a Trial | PRODUCT NAME: GALCANEZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/18/1330 20181116 |
| C201930047 | Spain | ⤷ Try a Trial | PRODUCT NAME: FREMANEZUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/19/1358; DATE OF AUTHORISATION: 20190328; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1358; DATE OF FIRST AUTHORISATION IN EEA: 20190328 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
